554 HYPERLIPOPROTEIN(A) AND PREMATURE CORONARY ARTERY DISEASE: A CALL FOR ACTION

Abstract Background and Aims elevated Lipoprotein (a) levels are well recognized as a genetic risk factor for atherothrombotic events. Recently, new therapeutic approaches – such small interfering RNA (siRNA) antisense oligonucleotides (ASOs) have been developed under evaluation in phase 3 trials. Evidences from literature suggest the need screening Lp(a) premature coronary artery disease. Aim of our study was to evaluate, real world scenario: 1) percentage CAD whom clinicians choose screen Lp(a); 2) prevalence hyperLp(a) CAD. Methods we retrospectively evaluated data patients admitted acute syndrome at Department Cardiology Careggi University Hospital, Florence, between 1st January 2018 31th July 2022. Inclusion criteria were: age < 50 years men 55 women; confirmed diagnosis with obstructive disease hospital discharge. Results selected 226 (50 F 176 M; total median 46 years, 49 M 45 years). LDL values admission were 117.12 mg/dl). Nine out pts (3.9%) had higher than 190 mg/dl, suggesting possible Heterozygous Familial Hypercholesterolemia (with respect expected general population: 1/250 (0.004%). No patient hepatic or thyroid Sixty-eight (30%) triglycerides 150 mg/dl; 41/226 (18.1%) 200 mg/dl. As regards levels, dosage performed 93/226 (41.2%). We found that lipoprotein required more frequently 2020, 2021 2022 (respectively 61%, 49% 70% patients) 2019 27% 23% (Figure 1). Among dosed, (> 300 mg/L) documented 45/93 (48.4%). 15/93 (16.1%) extreme 700 2). In two both other patients, only lipid parameter range, By comparing these an historical cohort ACS >50 yrs women respectively, multivariate analysis adjusted classical factors (OR:2.1 (95% CI 1.3–4.2), p<0.005) significantly associated (OR: 1.8 1.4–3.9); p<0.05). Conclusions results demonstrated that: it is urgent, clinical point view, apply protocols including dosage; particular population independently